China License Out

Announced Date: 2023-12-20 (December 20, 2023) Asset Name: HS-20093 Licensor: Hansoh Pharma  (Hansoh) (China) Licensee (Buyer): … [China BD Deal 2023] Hansoh and GSK enters a 1.71 billion USD license on B7-H3 ADC HS-20093Read more

Initial Announced Date: 2023-08-28 (August 28, 2025), Updated in 2023-12-18 (December 18, 2023) Asset: Three oncology … [China BD 2023] GenFleet and Verastem enters Collaboration, Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead ProgramRead more

Announced Date: 2023-12-11 (December 11, 2023) Asset Name: BL-B01D1 Licensor: SystImmune Inc., (a member of Sichuan … [China BD Deal 2023] SystImmune and BMS enters a 8.4 billion USD license on bispecific EGFRxHER3 ADC BL-B01D1Read more

Announced Date: 2023-11-20 (November 20, 2023) Asset Name: HSK31858 Licensor: Haisco Pharmaceutical Group (China) and Licensee … [China BD 2023] Haisco and Chiesi enters a 475 million USD license on DPP1 inhibitor HSK31858Read more

Announced Date: 2023-11-09 (November 9, 2023) Asset Name: ECC5004（AZD5004） Licensor: Eccogene (China) Licensee (Buyer): AstraZeneca（UK） . … [China BD 2023] Eccogene and AstraZeneca enters a 2 billion USD license on GLP-1RA ECC5004 (AZD5004)Read more

Announced Date: 2023-11-06 (November 6, 2023) Asset Name: PM8002 (BNT327) Licensor (Seller): Zhuhai Biotheus Inc (China) … [China BD 2023] Biotheus and BioNTech Enters the License on PD-L1/VEGF-A BsAbs PM8002 (BNT327)Read more

Announced Date: 2023-10-12 (October 12, 2023) Asset Name: YL202 (BNT326) Licensor (Seller): MediLink Therapeutics (China) Licensee … [China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC YL202 (BNT326)Read more

Announced Date: 2023-10-20 (October 20, 2023) Asset Name: HS-20089 Licensor: Hansoh Pharma  (Hansoh) (China) Licensee (Buyer): … [China BD Deal 2023] Hansoh and GSK enters a 1.57 billion USD license on B7-H4 ADC HS-20089Read more

Announced Date: 2023-09-12 (September 12, 2023) Asset Name: ISM3091 Licensor: InSilico Medicine (China) Licensee (Buyer): Exelixis, … [China BD 2023] Insilico Medicine and Exelixis enters a 800 million USD license on USP1 Inhibitor ISM3091Read more

Announced Date: 2023-05-12 (May 12, 2023) Asset Name: LM-299 Licensor (Seller): LaNova Medicines (LaNova) (China) Licensee … [China BD 2023] LaNova and AstraZeneca Enters a 600 million USD License on GPRC5D ADC LM-305Read more